Oncternal Therapeutics, Inc. ONCT
We take great care to ensure that the data presented and summarized in this overview for Oncternal Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ONCT
Top Purchases
Top Sells
About ONCT
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T) product candidate that targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.
Insider Transactions at ONCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 08
2024
|
Robert James Wills |
BUY
Open market or private purchase
|
Direct |
3,086
+23.58%
|
$24,688
$8.96 P/Share
|
|
Mar 28
2024
|
Robert James Wills |
BUY
Open market or private purchase
|
Direct |
6,914
+50.0%
|
$55,312
$8.48 P/Share
|
|
Feb 23
2024
|
Robert James Wills |
SELL
Open market or private sale
|
Direct |
980
-100.0%
|
$8,820
$9.04 P/Share
|
|
Feb 23
2024
|
David F Hale |
BUY
Open market or private purchase
|
Indirect |
266
+0.89%
|
$2,394
$9.04 P/Share
|
|
Feb 23
2024
|
David F Hale |
BUY
Open market or private purchase
|
Direct |
714
+50.0%
|
$6,426
$9.04 P/Share
|
|
Jan 03
2024
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,485
-22.53%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
50,955
-10.32%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
Chase C. Leavitt General Counsel/Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
11,838
-12.26%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
Richard G Vincent Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,868
-5.92%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
Salim Yazji Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,742
-13.31%
|
$0
$0.5 P/Share
|
|
Jan 03
2024
|
Rajesh Krishnan CTO/CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
11,838
-21.19%
|
$0
$0.5 P/Share
|
|
Jul 03
2023
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Indirect |
4,007
-16.75%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
James B Breitmeyer Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
47,992
-8.85%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
Rajesh Krishnan CTO/CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
10,897
-16.32%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
Salim Yazji Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
16,299
-9.9%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
Richard G Vincent Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,069
-4.51%
|
$0
$0.36 P/Share
|
|
Jul 03
2023
|
Chase C. Leavitt General Counsel/Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
10,305
-9.64%
|
$0
$0.36 P/Share
|
|
Jun 14
2023
|
Gunnar F. Kaufmann Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
3,000
+3.07%
|
$0
$0.36 P/Share
|
|
Jun 12
2023
|
Gunnar F. Kaufmann Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
25,000
+21.42%
|
$0
$0.35 P/Share
|
|
Apr 14
2023
|
James B Breitmeyer Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
50,000
+10.43%
|
$0
$0.3 P/Share
|
Last 12 Months Summary
| Open market or private purchase | 11K shares |
|---|
| Payment of exercise price or tax liability | 108K shares |
|---|---|
| Open market or private sale | 980 shares |